The law, which came into force at the start of 2018, has a broad scope spanning bribery, trademark infringement and other unfair practices across all industries. To support its implementation, SAMR is spending the next six months focusing on what it sees as key aspects of the law and its potential to level the playing field in Chinese business. Medicine is one of the target areas. SAMR wants to ensure purchases and sales of drugs and medical equipment are performed fairly. Types of malpractice targeted by SAMR include the use of property or other assets to bribe people and actions intended to secure trading opportunities or competitive advantages. China has cracked down on bribery in the pharmaceutical sector in the past, leading to the arrests of executives and penalties totalling hundreds of millions of dollars. More Information On RAPS